Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Synovial, skin gene expression differences may explain PsA treatment responses

Key clinical point: Different gene expression in synovial tissue, compared with skin, may explain differing treatment responses for skin and joints in psoriatic arthritis treated with anti-TNF agents and the anti–IL-23/IL-12 inhibitor ustekinumab.

Major finding: Some patients with psoriatic arthritis have lower levels of gene expression for key drug targets in their synovial tissues.

Study details: Observational, open-label study in 27 patients with active psoriatic arthritis.

Disclosures: The study was supported by the Queen Mary University of London and the Fondazione Ceschina, and in part by grants from Versus Arthritis. No conflicts of interest were declared.


Nerviani A et al. Ann Rheum Dis. 2020. Nov 26. doi: 10.1136/annrheumdis-2020-218186.